APA (7th ed.) Citation

AE, C., AM, M., MN, R., C, B., OO, O., F, H., . . . R, L. (2026). Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet (London, England), 407(10528), 611. https://doi.org/10.1016/S0140-6736(25)01948-8

Chicago Style (17th ed.) Citation

AE, Colson, et al. "Switch to Fixed-dose Doravirine (100 Mg) and Islatravir (0·25 Mg) Once Daily in Virologically Suppressed Adults with HIV-1 on Bictegravir, Emtricitabine, and Tenofovir Alafenamide: 48-week Results of a Phase 3, Multicentre, Randomised, Controlled, Double-blind, Non-inferiority Trial." Lancet (London, England) 407, no. 10528 (2026): 611. https://doi.org/10.1016/S0140-6736(25)01948-8.

MLA (9th ed.) Citation

AE, Colson, et al. "Switch to Fixed-dose Doravirine (100 Mg) and Islatravir (0·25 Mg) Once Daily in Virologically Suppressed Adults with HIV-1 on Bictegravir, Emtricitabine, and Tenofovir Alafenamide: 48-week Results of a Phase 3, Multicentre, Randomised, Controlled, Double-blind, Non-inferiority Trial." Lancet (London, England), vol. 407, no. 10528, 2026, p. 611, https://doi.org/10.1016/S0140-6736(25)01948-8.